AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
With a market cap of 253.55B, AstraZeneca(AZN) trades at $163.47. The stock has a price-to-earnings ratio of 24.31 and currently yields dividends of 1.68%.
On 2026-09-15, AstraZeneca(AZN) stock moved within a range of $160.71 to $163.90. With shares now at $163.47, the stock is trading +1.7% above its intraday low and -0.3% below the session's peak.
Trading activity shows a volume of 1.59M, compared to an average daily volume of 3.17M.
Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.
Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.
AZN News
...
An announcement from AstraZeneca ( (GB:AZN) ) is now available. AstraZeneca has disclosed a small share acquisition by its Chief Financial Officer, Dr Aradhana...
On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked AstraZeneca PLC (NYSE:AZN), Last week,...
Analyst ratings
100%
of 10 ratingsMore AZN News
Deutsche Bank upgraded AstraZeneca (AZN) to Hold from Sell with a price target of 11,700 GBp, up from 11,500 GBp. The firm cites valuation for the upgrade with...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new safety study tracks long-term use of eplontersen in patients wi...
AstraZeneca Plc (NYSE:AZN) reported updated clinical outcomes across its oncology portfolio, demonstrating sustained long-term survival advantages in lung cance...
Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca and keeping the price target at p16,500.00. Sachin Jain has given hi...
Stifel lowered the firm’s price target on Olema Oncology (OLMA) to $30 from $48 and keeps a Buy rating on the shares after AstraZeneca (AZN) announced on Friday...
Results from the DESTINY-Lung04 Phase III trial showed AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu demonstrated a statistically significant and clinically me...
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the SERENA-4 Phase III trial of Etcamah or camizestrant in combination with palbociclib did not meet t...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.